Filtered By:
Infectious Disease: Meningitis
Management: Funding

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 4 results found since Jan 2013.

Global, regional, and national burden of neurological disorders during 1990 –2015: a systematic analysis for the Global Burden of Disease Study 2015
Publication date: Available online 17 September 2017 Source:The Lancet Neurology Author(s): GBD 2015 Neurological Disorders Collaborator GroupValery LFeiginAmanuel AlemuAbajobirKalkidan HassenAbateFoadAbd-AllahAbdishakur MAbdulleSemaw FeredeAberaGebre YitayihAbyuMuktar BeshirAhmedAmani NidhalAichourIbtihelAichourMiloud Taki EddineAichourRufus OlusolaAkinyemiSamerAlabedRajaaAl-RaddadiNelsonAlvis-GuzmanAzmeraw T.AmareHosseinAnsariPalwashaAnwariJohanÄrnlövHamidAsayeshSolomon WeldegebrealAsgedomTesfay MehariAteyLeticiaAvila-BurgosEuripideFrinelG. ArthurAvokpahoAleksandraBaracMiguelBarbozaSuzanne LBarker-ColloTillBärnighaus...
Source: The Lancet Neurology - September 19, 2017 Category: Neurology Source Type: research

Qool Therapeutics raises $8m to support temp management device
Early stage med device developer Qool Therapeutics said today it raised $8 million in a Series A-1 round to support development and trials of its Qool device designed for targeted temperature management and exercise recovery. Joining the funding round was Zhongji Holdings and Join Medical Technology, Tampcap LLC, BrilliMedical International, BioPacific Investors, Western Technology Investment and FundRx, the Silicon Valley-based company said. Qool Therapeutics said that in addition to the funding, it has also received an award from the US Department of Defense’s Defense Innovation unit Experimental organization. The ...
Source: Mass Device - November 28, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Research & Development Respiratory qooltherapeutics Source Type: news

Tuberculosis Made Me Blind, But We Can Make Sure No One Else Needs to Suffer Like I Did
(function(){var src_url="https://spshared.5min.com/Scripts/PlayerSeed.js?playList=519608076&height=&width=100&sid=577&origin=undefined&videoGroupID=155847&relatedNumOfResults=100&responsive=true&ratio=wide&align=center&relatedMode=2&relatedBottomHeight=60&companionPos=&hasCompanion=false&autoStart=false&colorPallet=%23FFEB00&videoControlDisplayColor=%23191919&shuffle=0&isAP=1&pgType=cmsPlugin&pgTypeId=grabCodeLightbox&onVideoDataLoaded=HPTrack.Vid.DL&onTimeUpdate=HPTrack.Vid.TC";if (typeof(commercial_video) == "object") {src_url += "&siteSection="+commercial_video.site_and_category;if (commercial_video.package) {src_url +=...
Source: Healthy Living - The Huffington Post - March 24, 2016 Category: Consumer Health News Source Type: news

Pentraxin 3 in Cardiovascular Disease
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1 1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy 2Humanitas Clinical and Research Center-IRCCS, Milan, Italy 3Humanitas University, Milan, Italy 4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research